Long-term outcomes after transplantation after support with a pulsatile pediatric ventricular assist device.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
04 2019
Historique:
received: 22 12 2017
revised: 15 10 2018
accepted: 17 10 2018
pubmed: 24 11 2018
medline: 25 9 2020
entrez: 24 11 2018
Statut: ppublish

Résumé

There has been increasing use of durable ventricular assist devices (VAD) in children as a bridge to transplantation (BTT). The Berlin Heart investigational device exemption (IDE) trial was the first pediatric VAD trial to demonstrate excellent survival outcomes as a BTT. Our aim was to compare the expanded post-transplant outcomes for children enrolled in the Berlin Heart IDE trial to a matched Pediatric Heart Transplant Study (PHTS) cohort not requiring mechanical circulatory support (MCS). University Hospitals. This was a retrospective review of linked PHTS and Berlin Heart IDE databases for pediatric (≤18 years) recipients transplanted from 2007-2011. Subjects with <5 years of follow up were excluded. VAD supported patients were matched 1:2 to non-VAD supported controls from the PHTS database. Among 109 Berlin Heart IDE study enrollees, 83 were merged with the PHTS database and matched to 166 non-MCS supported patients. There was no difference in diagnosis, status at listing, and age between groups with the expected difference in inotrope use in the non-MCS supported patients. Compared to their matched cohort, there was no statistical difference in 5-year patient survival between VAD and non-VAD patients (81% vs 88%; p = 0.09) nor was there a difference in freedom from rejection or infection. This data suggests that children supported with a Berlin Heart VAD had similar survival, infection and rejection rates compared to those not requiring MCS support. Continued surveillance of the Berlin Heart IDE trial population post heart transplantation is warranted.

Sections du résumé

BACKGROUND
There has been increasing use of durable ventricular assist devices (VAD) in children as a bridge to transplantation (BTT). The Berlin Heart investigational device exemption (IDE) trial was the first pediatric VAD trial to demonstrate excellent survival outcomes as a BTT.
OBJECTIVES
Our aim was to compare the expanded post-transplant outcomes for children enrolled in the Berlin Heart IDE trial to a matched Pediatric Heart Transplant Study (PHTS) cohort not requiring mechanical circulatory support (MCS).
SETTING
University Hospitals.
METHODS
This was a retrospective review of linked PHTS and Berlin Heart IDE databases for pediatric (≤18 years) recipients transplanted from 2007-2011. Subjects with <5 years of follow up were excluded. VAD supported patients were matched 1:2 to non-VAD supported controls from the PHTS database.
RESULTS
Among 109 Berlin Heart IDE study enrollees, 83 were merged with the PHTS database and matched to 166 non-MCS supported patients. There was no difference in diagnosis, status at listing, and age between groups with the expected difference in inotrope use in the non-MCS supported patients. Compared to their matched cohort, there was no statistical difference in 5-year patient survival between VAD and non-VAD patients (81% vs 88%; p = 0.09) nor was there a difference in freedom from rejection or infection.
CONCLUSIONS
This data suggests that children supported with a Berlin Heart VAD had similar survival, infection and rejection rates compared to those not requiring MCS support. Continued surveillance of the Berlin Heart IDE trial population post heart transplantation is warranted.

Identifiants

pubmed: 30466802
pii: S1053-2498(18)31723-6
doi: 10.1016/j.healun.2018.10.005
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

449-455

Informations de copyright

Copyright © 2018 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Aamir Jeewa (A)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US. Electronic address: aamir.jeewa@sickkids.ca.

Michiaki Imamura (M)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Charles Canter (C)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Robert A Niebler (RA)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Christina VanderPluym (C)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

David N Rosenthal (DN)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

James K Kirklin (JK)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Ryan S Cantor (RS)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Margaret Tresler (M)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

David Michael McMullan (DM)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Victor O Morell (VO)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Mark Turrentine (M)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Rebecca Ameduri (R)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Khanh Nguyen (K)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Kirk Kanter (K)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Jennifer Conway (J)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Robert Gajarski (R)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Charles D Fraser (CD)

Division of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, US.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH